Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months - Concepedia

Concepedia

Publication | Open Access

Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months

DOI Full Paper Access

58

Citations

19

References

2022

Year

Guruprasad R. Medigeshi, Gaurav Batra, Deepika Rathna Murugesan, Ramachandran Thiruvengadam, Souvick Chattopadhyay, Bhabatosh Das, Mudita Gosain, Ayushi Ayushi, Janmejay Singh, Anbalagan Anantharaj,

Abstract

Department of Biotechnology, India; Bill & Melinda Gates Foundation, USA.

References

	Year	Citations
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection David S. Khoury, Deborah Cromer, Arnold Reynaldi, Nature Medicine Humoral ResponseImmunologyAntiviral ResponseHumoral ImmunityImmune Protection	2021	4.1K
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift Elisabetta Cameroni, John E. Bowen, Laura E. Rosen, Nature VaccinationNeutralizing AntibodiesVaccine TargetHumoral ResponseImmunology	2021	1.2K
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis The Lancet Microbe	2021	598
SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells Hanjun Zhao, Lu Lu, Peng Zheng, Emerging Microbes & Infections Viral PathogenesisImmunologyPathologyImmunodominanceImmune Regulation	2021	467
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients Lu Lu, Bobo Wing-Yee Mok, Lin Lei Chen, Clinical Infectious Diseases	2021	382
Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost Jingwen Ai, H. C. Zhang, Yi Zhang, Emerging Microbes & Infections	2021	373
Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies Alexander Wilhelm, Marek Widera, Katharina Grikscheit, VaccinationSars-cov-2 Omicron VariantSpike ProteinVaccine DevelopmentVaccine Sera	2021	368
SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection Sandile Cele, Laurelle Jackson, David S. Khoury, VaccinationIncomplete EscapePfizer Bnt162b2Viral PersistenceVaccine Development	2021	361
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses Jordan R. Barrett, Sandra Belij‐Rammerstorfer, Christina Dold, Nature Medicine VaccinationPhase 1/2Vaccine DevelopmentImmunologyHumoral Immunity	2020	334
Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays Kevin R. Bewley, Naomi S. Coombes, Luc Gagnon, Nature Protocols Virus Neutralization AssaysViral DiagnosticsViral PathogenesisImmunologyAntiviral Response	2021	317

Page 1